TABLE 4.
Homocysteine and incident CRC: comparison of studies1
| Study (reference) | Study sample | Outcome2 |
| Northern Sweden Health and Disease cohort (15) | Cases: 94 M/132 FControls: 184 M/253 F | Highest Hcy quintile (>15.1 μmol/L) vs lowest quintile (≤9.7 μmol/L); OR: 1.12 (95% CI: 0.63, 1.99), NS |
| Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (16) | Cases: 275 MControls: 275 M | Highest Hcy quintile (18.8 μmol/L) vs lowest quintile (9.2 μmol/L); OR: 1.22 (95% CI: 0.68, 2.17), NS |
| Multiethnic Cohort Study (17) | Cases: 140 M/84 FControls: 257 M/154 F | Highest Hcy quartile (>11.8 μmol/L) vs lowest quartile (≤7.65 μmol/L); OR: 1.00 (95% CI: 0.56, 1.79), NS |
| Physician's Health Study (18) | Cases: 197 MControls: 371 M | Cases: median Hcy = 11 μmol/LControls: median Hcy = 10 μmol/LNo difference in medians (P = 0.13) |
| Women's Health Initiative observational cohort | Cases: 988 FControls: 988 F | Highest Hcy quartile (>9.85 μmol/L) vs lowest quartile (≤6.74 μmol/L); OR: 1.46 (95% CI: 1.05, 2.04), P = 0.02 |
1
CRC, colorectal cancer; Hcy, homocysteine.
2
ORs (95% CIs) are for all forms of CRC and are multivariate adjusted.